Brain Metastases

Oncology
9
Pipeline Programs
12
Companies
11
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
6
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 9 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
3 programs
2
Preoperative RadiotherapyPhase 21 trial
SRSPhase 21 trial
RadiationN/A1 trial
Active Trials
NCT04084431Suspended40Est. Jul 2025
NCT05871307Recruiting90Est. May 2028
NCT05378633Recruiting190Est. Feb 2028
E
EisaiChina - Liaoning
1 program
1
PembrolizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05064280Recruiting104Est. Feb 2028
Aura Biosciences
Aura BiosciencesMA - Boston
1 program
1
Preoperative SRSPhase 21 trial
Active Trials
NCT04503772CompletedEst. Nov 2025
Pfizer
PfizerNEW YORK, NY
1 program
1
TrastuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05323955Active Not Recruiting48Est. Jul 2026
Biogen
BiogenCAMBRIDGE, MA
1 program
1
berubicin hydrochloridePhase 21 trial
Active Trials
NCT00538343Terminated14Est. Jan 2009
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
Stereotactic RadiosurgeryPhase 1/21 trial
Active Trials
NCT04923542Recruiting31Est. Dec 2026
Kazia Therapeutics
Kazia TherapeuticsAustralia - Sydney
1 program
1
GDC-0084Phase 11 trial
Active Trials
NCT04192981Active Not RecruitingEst. Dec 2026
EpicentRx
EpicentRxCA - La Jolla
1 program
1
RRx-001 + WBRTPhase 11 trial
Active Trials
NCT02215512CompletedEst. Nov 2020
Siemens Healthineers
Siemens HealthineersGermany - Forchheim
1 program
Stereotactic radiosurgeryN/A1 trial
Active Trials
NCT05270707CompletedEst. Mar 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Heidelberg PharmaPreoperative Radiotherapy
PfizerTrastuzumab
EisaiPembrolizumab
Aura BiosciencesPreoperative SRS
Biogenberubicin hydrochloride
Eli Lilly and CompanyStereotactic Radiosurgery
Kazia TherapeuticsGDC-0084
EpicentRxRRx-001 + WBRT
Siemens HealthineersStereotactic radiosurgery
Heidelberg PharmaSRS
Heidelberg PharmaRadiation

Clinical Trials (11)

Total enrollment: 517 patients across 11 trials

NCT05871307Heidelberg PharmaPreoperative Radiotherapy

Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases

Start: Feb 2024Est. completion: May 202890 patients
Phase 2Recruiting
NCT05323955PfizerTrastuzumab

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

Start: Mar 2023Est. completion: Jul 202648 patients
Phase 2Active Not Recruiting
NCT05064280EisaiPembrolizumab

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Start: Jan 2022Est. completion: Feb 2028104 patients
Phase 2Recruiting
NCT04503772Aura BiosciencesPreoperative SRS

Preoperative Stereotactic Radiosurgery for Brain Metastases

Start: Feb 2021Est. completion: Nov 2025
Phase 2Completed
NCT00538343Biogenberubicin hydrochloride

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Start: Oct 2007Est. completion: Jan 200914 patients
Phase 2Terminated
NCT04923542Eli Lilly and CompanyStereotactic Radiosurgery

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

Start: Nov 2021Est. completion: Dec 202631 patients
Phase 1/2Recruiting
NCT04192981Kazia TherapeuticsGDC-0084

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

Start: Dec 2019Est. completion: Dec 2026
Phase 1Active Not Recruiting
NCT02215512EpicentRxRRx-001 + WBRT

Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases

Start: Feb 2015Est. completion: Nov 2020
Phase 1Completed
NCT05270707Siemens HealthineersStereotactic radiosurgery

HyperArc Registry Study

Start: Mar 2022Est. completion: Mar 2025
N/ACompleted
NCT05378633Heidelberg PharmaSRS

The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?

Start: Feb 2022Est. completion: Feb 2028190 patients
N/ARecruiting
NCT04084431Heidelberg PharmaRadiation

Supportive Care With or Without Repeated Whole Brain Radiotherapy in Patients With Recurrent Brain Metastases

Start: Jul 2019Est. completion: Jul 202540 patients
N/ASuspended

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 517 patients
12 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)